NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $1.61 0.00 (0.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 10/3/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Autolus Therapeutics Stock (NASDAQ:AUTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Autolus Therapeutics alerts:Sign Up Key Stats Today's Range$1.57▼$1.6450-Day Range$1.27▼$2.5152-Week Range$1.11▼$5.00Volume2.32 million shsAverage Volume4.90 million shsMarket Capitalization$428.49 millionP/E RatioN/ADividend YieldN/APrice Target$9.12Consensus RatingModerate Buy Company Overview Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications. The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma. Additional clinical and preclinical programs address targets such as BCMA in multiple myeloma and solid tumor antigens, as well as novel constructs aimed at improving T cell persistence and tumor microenvironment penetration. Autolus collaborates with academic institutions and research partners to advance its pipeline and validate emerging technologies. Founded in 2014 as a spin-out from University College London, Autolus is headquartered in London, U.K., with operational sites in the United States and Europe to support clinical trials and manufacturing scale-up. The company is led by Chief Executive Officer Christian Itin, whose background in cell therapy and immuno-oncology guides a leadership team of experienced industry executives and scientific experts. Autolus is committed to expanding global access to its therapies through regulatory filings and strategic partnerships in key markets.AI Generated. May Contain Errors. Read More Autolus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreAUTL MarketRank™: Autolus Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 398th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAutolus Therapeutics has a consensus price target of $9.12, representing about 466.5% upside from its current price of $1.61.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Autolus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.99% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 4.95%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.99% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 4.95%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News SentimentN/A News SentimentAutolus Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Autolus Therapeutics this week, compared to 4 articles on an average week.Search Interest36 people have searched for AUTL on MarketBeat in the last 30 days. This is an increase of 414% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUTL Stock News HeadlinesAutolus Therapeutics (NASDAQ:AUTL) Receives Outperform Rating from William BlairSeptember 26, 2025 | americanbankingnews.comAutolus Therapeutics announces abstract submitted to ACR Convergence 2025September 16, 2025 | msn.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 5 at 2:00 AM | StockEarnings (Ad)Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025September 16, 2025 | globenewswire.comNeedham Keeps Buy Rating on Autolus (AUTL) with a $10 TargetAugust 24, 2025 | msn.comAutolus Therapeutics Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comAutolus Therapeutics PLC (AUTL) Q2 2025 Earnings Call Highlights: Strong Product Sales Amid ...August 13, 2025 | finance.yahoo.comAutolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From ProfitableAugust 12, 2025 | seekingalpha.comSee More Headlines AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $2.35 on January 1st, 2025. Since then, AUTL shares have decreased by 31.5% and is now trading at $1.61. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business earned $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. Read the conference call transcript. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings8/12/2025Today10/05/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUTL CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees330Year Founded2014Price Target and Rating Average Price Target for Autolus Therapeutics$9.12 High Price Target$13.00 Low Price Target$5.00 Potential Upside/Downside+466.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$220.66 million Net MarginsN/A Pretax Margin-747.21% Return on Equity-56.18% Return on Assets-29.61% Debt Debt-to-Equity RatioN/A Current Ratio8.43 Quick Ratio8.07 Sales & Book Value Annual Sales$10.12 million Price / Sales42.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book1.00Miscellaneous Outstanding Shares266,140,000Free Float197,743,000Market Cap$428.49 million OptionableOptionable Beta1.84 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:AUTL) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.